BioCardia(US:BCDA)2025-03-26 21:20Financial Performance - Net cash used in operations was approximately $8.0 million in 2024, a decrease from approximately $10.0 million in 2023[9] - Revenues for 2024 were approximately $58,000, down from approximately $477,000 in 2023, primarily due to the fulfillment of performance obligations[9] - Research and development expenses decreased to approximately $4.4 million in 2024 from approximately $7.7 million in 2023, reflecting reduced clinical expenses[9] - Selling, general and administrative expenses decreased to approximately $3.7 million in 2024 from approximately $4.4 million in 2023, due to personnel realignment and cost reductions[9] - The net loss for 2024 was approximately $7.9 million, compared to approximately $11.6 million in 2023[9] - Cash and cash equivalents at the end of 2024 totaled $2.4 million, an increase from $1.1 million at the end of 2023[17] Clinical Trials and Developments - The CardiAMP HF Trial's last protocol-specified follow-up visit has been completed, with data analysis nearing completion for presentation at the American College of Cardiology Scientific Sessions[5] - The first commercial Morph DNA steerable introducer devices have been manufactured and are now available for use in clinical trials and procedures[6] - The company anticipates finalizing the initial trial manuscript for publication and accelerating enrollment activities in the CardiAMP HF II Trial in the coming weeks[5] - The company is preparing for a consultation with Japan's PMDA regarding the registration of the CardiAMP Cell Therapy System for heart failure treatment[5]